Vanessa Chisholm

TL;DR: Rec recombinant humanized MAb V EGF is suitable to test the hypothesis that inhibition of VEGF-induced angiogenesis is a valid strategy for the treatment of solid tumors and other disorders in humans.

TL;DR: The unexpected finding that treatment with truncated soluble Flt-1 receptors, which inhibit vascular endothelial growth factor (VEGF) bioac-tivity, resulted in virtually complete suppression of CL angiogenesis in a rat model of hormonally induced ovulation is reported.

TL;DR: The experiments demonstrate the feasibility of genetically engineering cell lines to produce therapeutics with desired glycosylation patterns and resulted in reduction of oligosaccharides terminating with GlcNAc, whereas overexpression of ST resulted in sialylation of ≥90% of available branches.

TL;DR: These vectors produce stable CHO cell clones that, when pooled, produce abundant amounts of secreted recombinant proteins compared with the amounts produced by conventional expression approaches that have selectable marker and the cDNA of interest under control of separate transcription units.

TL;DR: This work evaluated using green fluorescent protein (GFP) for selection of high producing clones by fluorescence-activated cell sorter (FACS) to reduce screening effort in Chinese hamster ovary cells and found that productivity correlated very well with RNA of the desired protein.